title: Current issues in vaccines for adult patients with hematologic malignancies.
abstract: Vaccination is an important strategy for preventing infections in patients with hematologic malignancies. Hematopoietic cell transplant (HCT) recipients have diminished immunity against vaccine-preventable diseases after transplantation. Optimal timing for initiating immunization in the context of hematologic malignancies and after HCT, however, is not well defined, and data on the magnitude and duration of immune response to vaccines in this population are lacking. Factors such as degree of immunosuppression, administration of monoclonal antibodies, time after HCT, and presence or absence of chronic graft-versus-host disease may influence the immune response to vaccines and may pose safety concerns for certain vaccines, such as live-attenuated immunogens. Patients who received certain monoclonal antibodies (eg, rituximab, alemtuzumab) less than 6 months before vaccination have poorer immune responses to vaccines. New advancements in vaccine development are warranted to improve safety and immunogenicity of vaccination in immunocompromised patients.
authors.affiliation: Division of Infectious Diseases, Brigham & Women's Hospital; Dana-Farber Cancer Institute, 75 Francis St., Boston, MA 02115, USA. nissa@partners.org
authors.forename: Nicolas C
authors.initials: NC
authors.lastname: Issa
authors.forename: Lindsey R
authors.initials: LR
authors.lastname: Baden
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000276:immunology; D019337:Hematologic Neoplasms / Q000150:complications* / Q000276:immunology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D007251:Influenza, Human / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D018410:Pneumonia, Bacterial / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated; D018074:Vaccines, Conjugate; D014765:Viral Vaccines